MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation

Journal of Clinical Investigation

Volumn 123, Issue 5, 2013, Pages 1939-1951

  Luo, Xiaobin ^a,b,c   Pan, Zhenwei ^c   Shan, Hongli ^c   Xiao, Jiening ^a   Sun, Xuelin ^c   Wang, Ning ^c   Lin, Huixian ^a   Xiao, Ling ^a,b,d   Maguy, Ange ^a   Qi, Xiao Yan ^a   Li, Yue ^e   Gao, Xu ^c   Dong, Deli ^c   Zhang, Yong ^c   Bai, Yunlong ^c   Ai, Jing ^c   Sun, Lihua ^c   Lu, Hang ^c   Luo, Xiao Yan ^a   Wang, Zhiguo ^c   Lu, Yanjie ^c   Yang, Baofeng ^c   Nattel, Stanley ^a,b,d   more..

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d MCGILL UNIVERSITY   (Canada)

^e THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; MESSENGER RNA; MICRORNA; MICRORNA 26; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; EMBRYO; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; TRANSCRIPTION REGULATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

EID: 84877132387     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI62185     Document Type: Article

References (48)

1. Yang B, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med. 2007;13(4):486-491.
2. Carè A, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13(5):613-618.
3. Feng B, et al. miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev. 2010; 26(1):40-49.
4. K1 up-regulation in human atrial fibrillation. Heart Rhythm. 2009;6(12):1802-1809.
5. Lu Y, et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation. 2010;122(23):2378-2387.
6. 2+ release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ Res. 2009;104(4):514-521.
7. Zhao Y, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell. 2007;129(2):303-317.
8. Matkovich SJ, et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res. 2010; 106(1):166-175.
9. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 2002;415(6868):219-226.
10. Nattel S, Maguy A, Le Bouter S, Yeh YH. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev. 2007;87(2):425-456.
11. K1 in action potential shortening associated with atrial fibrillation in humans. Cardiovasc Res. 2005;66(3):493-502.
12. Bosch RF, Zeng X, Grammer JB, Popovic CM, Kuhlkamp V. Ionic mechanisms of electrical remodelling in human atrial fibrillation. Cardiovasc Res. 1999;44(1):121-131.
13. Workman AJ, Kane KA, Rankin AC. The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. Cardiovasc Res. 2001;52(2):226-235.
14. Cha TJ, Ehrlich JR, Zhang L, Nattel S. Atrial ionic remodelling induced by atrial tachycardia in the presence of congestive heart failure. Circulation. 2004;110(12):1520-1526.
15. Dobrev D, et al. Human inward rectifier potassium channels in chronic and postoperative atrial fibrillation. Cardiovasc Res. 2002;54(2):397-404.
16. Gaborit N, et al. Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation. 2005;112(4):471-481.
17. Atienza F, et al. Activation of inward rectifier potassium channels accelerates atrial fibrillation in humans: evidence for a reentrant mechanism. Circulation. 2006;114(23):2434-2442.
18. Pandit SV, et al. Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. Biophys J. 2005; 88(6):3806-3821.
19. Katsouras G, et al. Differences in atrial fibrillation properties under vagal nerve stimulation versus atrial tachycardia remodeling. Heart Rhythm. 2009; 6(10):1465-1472.
20. Noujaim SF, et al. Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets. FASEB J. 2010;24(11):4302-4312.
21. Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics. 2007;8:166.
22. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15-20.
23. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res. 2007; 100(3):416-424.
24. Nigam V, et al. Altered microRNAs in bicuspid aortic valve: a comparison between stenotic and insufficient valves. J Heart Valve Dis. 2010;19(4):459-465.
25. Lanford RE, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327(5962):198-201.
26. Elmén J, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008; 452(7189):896-899.
27. Grünweller A, Hartmann RK. Locked nucleic acid oligonucleotides: the next generation of antisense agents? Bio Drugs. 2007;21(4):235-243.
28. Wang Z. The principles of miRNA-masking antisense oligonucleotides technology. Methods Mol Biol. 2011;676:43-49.
29. Kota J, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137(6):1005-1017.
30. Lin CC, et al. Activation of the calcineurin-nuclear factor of activated T-cell signal transduction pathway in atrial fibrillation. Chest. 2004;126(6):1926-1932.
31. Qi XY, et al. Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current. Circ Res. 2008;103(8):845-854.
32. 2+ signaling and gene expression. J Physiol. 2004;554(pt 2):309-320.
33. Nattel S, Burstein B, Dobrev D. Atrial remodelling and atrial fibrillation: Mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1(1):62-73.
34. Priori SG, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res. 2005;96(7):800-804.
35. Xia M, et al. A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun. 2005;332(4):1012-1019.
36. Wakili R, Voigt N, Kääb S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011;121(8):2955-2968.
37. K1) controls cardiac excitability and is involved in arrhythmogenesis. Heart Rhythm. 2005;2(3):316-324.
38. Wang Z, Yue L, White M, Pelletier G, Nattel S. Differential expression of inward rectifier potassium channel mRNA in human atrium versus ventricle and in normal versus failing hearts. Circulation. 1998; 98(22):2422-2428.
39. Dobrev D, Carlsson L, Nattel S. Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov. 2012;11(4):275-291.
40. Amit G, Qin H, Donahue JK. Biological therapies for atrial fibrillation. J Cardiovasc Pharmacol. 2008; 52(3):222-227.
41. Harada M, et al. Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation. 2012; 126(17):2051-2064.
42. Schrickel JW, et al. Induction of atrial fibrillation in mice by rapid transesophageal atrial pacing. Basic Res Cardiol. 2002;97(6):452-460.
43. Luo X, Zhang H, Xiao J, Wang Z. Regulation of human cardiac ion channel genes by microRNAs: Theoretical perspective and pathophysiological implications. Cell Physiol Biochem. 2010;25(6):571-586.
44. Lin H, Xiao J, Luo X, Pan Z, Yang B, Wang Z. Transcriptional control of pacemaker channel genes HCN2 and HCN4 by Sp1 and implications in reexpression of these genes in hypertrophic heart. Cell Physiol Biochem. 2009;23(4-6):317-326.
45. Luo X, Xiao J, Lin H, Lu Y, Yang B, Wang Z. Genomic structure, transcriptional control and tissue distribution of human ERG1 and KCNQ1 genes. Am J Physiol. 2007;294(3):H1371-H1380.
46. van Rooij E, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA. 2006;103(48):18255-18260.
47. Gao H, et al. A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anti-cancer effects. Mol Pharmacol. 2006; 70(5):1621-1629.
48. Xiao J, Lin H, Luo X, Luo X-Y, Wang Z. miR-605 joins p53 network to form a p53:miR-605: Mdm2 positive feedback loop in response to stress. EMBO J. 2011;30(3):524-532.